After seven years of sharpening, the phase I clinical trial of YK012 for injection was officially launched recently.

YK012  for injection is a new generation of safe, high-yield, long-acting and  low-cost bispecific antibody drug independently developed by our company  for the treatment of non-Hodgkin's lymphoma (NHL), which belongs to  innovative class 1 new drug.  We will continue to work hard to achieve the early listing of YK012 for  injection at home and abroad and benefit tumor patients!